New hope for newborn seizures: higher drug dose under study

NCT ID NCT05610085

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 18 times

Summary

This study tests whether higher doses of the seizure drug levetiracetam can safely control seizures in newborns. About 133 full-term infants with seizures or at risk for them will receive the medicine and be monitored with continuous EEG. The goal is to find the best dose that stops seizures with minimal side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPOXIC-ISCHEMIC ENCEPHALOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Auckland City Hospital

    RECRUITING

    Auckland, Auckland, 1023, New Zealand

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Capital and Coast District Health Board, Te Whatu Ora, Health New Zealand

    RECRUITING

    Wellington, Wellington Region, 6021, New Zealand

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Middlemore Hospital

    RECRUITING

    Auckland, Auckland, 1050, New Zealand

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of California, San Diego

    RECRUITING

    San Diego, California, 92093, United States

    Contact Email: •••••@•••••

  • University of Minnesota

    RECRUITING

    Minneapolis, Minnesota, 55455, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.